Wnt signaling pathway
May 06, 2019
Wnt Signaling Pathway Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years
Wnt signaling pathway plays
an important role in embryonic development. The signaling pathway regulates
cell-to-cell interaction, accelerates trophoblast development, activates
blastocyst, accelerate chorion-allantois fusion and implantation. A wide range
of diseases, such as different types of cancer and degenerative diseases can be
treated by deregulation of components involved in Wnt/β-catenin signaling
pathway. Also, researchers have demonstrated that moderate weakening of Wnt
signaling can eliminate its carcinogenic potential. Based on the recent
researches, Wnt Signaling Pathway inhibitors have also shown potential in
cardiovascular disorders.
Get a sample report at: https://www.pharmaproff.com/request-sample/1210
Get a sample report at: https://www.pharmaproff.com/request-sample/1210
According to the research
findings, majority of the drug candidates in the pipeline are being developed
to be administered by the oral route. It has been observed that oral route of
medications is convenient; available in delayed or rapid release formulation;
provides improved patient’s compliance; and has less risk of systemic
infections. Administration of Wnt Signaling Pathway Inhibitors through oral
route has shown promising results in the clinical studies. Also, according to
the analysis, maximum number of drugs in the pipeline are being developed as
small molecules.
The companies developing Wnt Signaling Pathway inhibitors for the
treatment of cancer and degenerative diseases, have shown positive clinical
results in the various phases of drug development. For instance, in October
2018, Samumed LLC, announced the topline data from the phase IIb trial SM04690
in knee osteoarthritis, wherein the treatment with SM04690 showed improvement
in function, pain, and global scores of patients.
Some of the key players
involved in the development of Wnt signaling pathway inhibitors in the late and
mid stage include Samumed LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics
Inc., Leap Therapeutics Inc., 2X Oncology Inc., Eisai Co. Ltd., and Novartis
AG.
